Rudra Prasad Dutta

Employment

Employment history is unavailable.

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (19)

• Discovery of a Potent, Selective, and In Vivo Efficacious Covalent Inhibitor for Lysine Methyltransferase SETD8.
  Journal of medicinal chemistry 2026 DOI: 10.1021/acs.jmedchem.5c02958
  +Save
• Therapeutic Targeting of SETD8 Suppresses Multiple Myeloma Growth Through the IRF4/MYC Axis
  Clinical Lymphoma Myeloma and Leukemia 2026 DOI: 10.1016/s2152-2650(26)02982-4
  +Save
• Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell Therapy
  New England Journal of Medicine 2025
  +Save
• TET2 and EZH2 Genetic Alterations Promote Malignant CAR-T Transformation in Anti-BCMA CAR-T Therapy
  Clinical Lymphoma Myeloma and Leukemia 2025 DOI: 10.1016/s2152-2650(25)03405-6
  +Save
• S100A8/A9 Promotes T Cell Exhaustion and Impairs Response to Bispecific Therapy in Multiple Myeloma
  Clinical Lymphoma Myeloma and Leukemia 2025 DOI: 10.1016/s2152-2650(25)03419-6
  +Save
• Shared immune features correspond to high-risk multiple myeloma across multiple human subtypes and murine models
  Blood 2025 DOI: 10.1182/blood-2025-5723
  +Save
• S100A8/A9 drives T cell exhaustion and compromises the therapeutic efficacy of bispecific antibodies in multiple myeloma.
  Blood 2025 DOI: 10.1182/blood-2025-916
  +Save
• Genomic alterations in TET2 and EZH2 serve as critical drivers of clonal malignant evolution in anti-BCMA CAR-T therapy for multiple myeloma.
  Blood 2025 DOI: 10.1182/blood-2025-3946
  +Save
• Epigenetic targeting of SETD8 in multiple myeloma
  Blood 2025 DOI: 10.1182/blood-2025-3310
  +Save
• SOX11 modulates BCR signaling through the PAX5/CD19 axis for therapeutic targeting in BTK-resistant mantle cell lymphoma
  Blood Advances 2025 DOI: 10.1182/bloodadvances.2025016801
  +Save